Inquis Medical Raises Financing for Commercialization of Aventus Thrombectomy System

January 14, 2026—Inquis Medical, Inc., a privately held medical device company focused on mechanical thrombectomy for venous thromboembolic disease, announced the closing of a $75 million Series C financing round.

According to the company, the investment will be used to accelerate nationwide commercial expansion of the company’s Aventus mechanical thrombectomy system and advance the company’s next-generation product pipeline.

The company stated that with the completion of this round, Inquis Medical will expand its sales and physician-training infrastructure while continuing to grow its clinical evidence base. The latest financing, which was provided by an undisclosed strategic investor, builds on the $40 million Series B financing led by Marshall Wace in August 2024.

Inquis Medical advised that it transitioned into a commercial-stage organization in the past year.

In June 2025, the company announced that the Aventus system received FDA 510(k) clearance for an expanded indication to treat pulmonary embolism (PE). The device was previously cleared for use in the peripheral vasculature.

In May 2025, the company announced the presentation and publication of results from the AVENTUS pivotal trial data demonstrating significant thrombus removal while minimizing blood loss through integrated autologous blood reinfusion in 130 patients with intermediate-risk PE with no device-related adverse events.

Jun Li, MD, presented the findings at the Society for Cardiovascular Angiography & Interventions 2025 scientific sessions. The results were simultaneously published by Saher Sabri, MD, et al in JSCAI. Drs. Li and Sabri are National Coprincipal Investigators of the AVENTUS trial.